Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Objective To discuss the efficacy and safety of novel and emerging topical and systemic
therapeutic agents for atopic dermatitis (AD). Data Sources The review of the published …

Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

Background Children with severe atopic dermatitis (AD) have limited treatment options.
Objective We report the efficacy and safety of dupilumab+ topical corticosteroids (TCS) in …

Given the lack of head‐to‐head studies of systemic therapies in moderate‐to‐severe atopic
dermatitis (AD), network meta‐analyses (NMAs) can provide comparative efficacy and safety …

Abstract In December 2019, China reported the first cases of the coronavirus disease 2019
(COVID‐19). This disease, caused by the severe acute respiratory syndrome–related …

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense
pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a …

Background Although atopic dermatitis (AD) often presents in infancy and persists into
adulthood, comparative characterization of AD skin among different pediatric age groups is …

Background For adolescent patients (aged≥ 12 to< 18 years) with uncontrolled moderate-to-
severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial …

Background Moderate‐to‐severe atopic dermatitis (AD) often requires long-term
management with systemic therapies. Objective Our objective was to report the safety and …